Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research

Numinus Wellness and Novamind have announced that they have entered into a definitive arrangement agreement pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately C$26.2 million on a fully diluted in-the-money basis.

Category Press Release
Published in Novamind

Companies Featured

Novamind
Novamind has bold plans for building out a psychedelic ecosystem. One that spans from ketamine-assisted psychotherapy and psilocybin retreats to novel clinical trials.

Numinus
Numinus is a Canadian company trying to create a platform for the therapeutic use of psychedelics. Working together with researchers, yet also wanting to see how to make it commercially viable. The two founders both came here from personal experiences.